Target intelligence / Profile preview

SLC9A9 antisense RNA 1 (SLC9A9-AS1)

Target: SLC9A9-AS1
Molecular classification: Long non-coding RNA (lncRNA), Antisense RNA, Other

Overview

SLC9A9 antisense RNA 1 (SLC9A9-AS1) is a long non-coding RNA (lncRNA) transcribed in the antisense direction from the SLC9A9 gene locus. It does not encode a protein. SLC9A9-AS1 has been shown to function as a competitive endogenous RNA (ceRNA), acting by sequestering specific microRNAs (miRNAs) and thereby modulating the expression of downstream genes. For example, in nasopharyngeal carcinoma, SLC9A9-AS1 sponges miR-486-5p, leading to upregulation of E2F transcription factor 6 (E2F6), promoting cancer cell proliferation, migration, invasion, and suppressing apoptosis[2]. Elevated SLC9A9-AS1 expression is associated with poorer survival in patients with nasopharyngeal carcinoma. Its role as a ceRNA links it to oncogenesis and suggests potential utility as a biomarker or diagnostic tool in cancer settings[2][3]. However, SLC9A9-AS1 is not a receptor, enzyme, transporter, or typical therapeutic target, but an RNA-based regulator implicated in the modification of disease processes[3][4].

Other names: SLC9A9-AS1SLC9A9 antisense RNA 1 (non-protein coding)

Biological functions

Regulation of gene expressionCompetitive endogenous RNA (ceRNA) activityModulation of cell proliferationApoptosisRegulation of tumorigenesis

Disease associations

Cancer (notably nasopharyngeal carcinoma, lung cancer)Other

Biomarkers

Proposed prognostic and diagnostic biomarker (for nasopharyngeal carcinoma, potentially for lung cancer)[2]

Beyond the preview

Go deeper on SLC9A9 antisense RNA 1 (SLC9A9-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLC9A9 antisense RNA 1 (SLC9A9-AS1).

Explore the full profile